While in the VERTU trial, veliparib with chemoradiation and TMZ combination was evaluated in MGMT-unmethylated GBM, demonstrating that this association is also well tolerated but did not improve outcomes [46,47]. The gene discussed is MGMT; the disease is glioblastoma.